Experimental Hematology Grants

Grant and Contract AwardsAnnual Direct

Akunuru, S

Training Programs in Cancer Therapeutics
T32 CA 11784609/14/12-08/31/14$42,862

Cancelas-Perez, J

Rational Design of a Vav/Rac Inhibitor as a New Therapy for High-Risk B-ALL
10/01/12-09/30/15$180,018
Validation of a Rationally Designed Guanine Nucleotide Exchange Factor Inhibitor in Lymphoblastic Leukemia
01/01/14-12/31/16$70,000

Degen, J

Analysis of Staphylococcus Aureus Host Interactions
R01 AI 02062409/01/12-08/31/15$46,736

Degen, J / Malik P

Hemostatic Factors and Sickle Cell Disease
R01 HL 11260301/01/12-11/30/16$245,000

Filippi, M

Regulation of Neutrophil Migration and Polarity
R01 HL 09067603/01/10-02/28/15$242,550

Flick, M

Mechanisms Linking the Hemostatic Protease Thrombin to Arthritic Disease
R01 AR 05699008/10/09-07/31/14$162,518
Cincinnati Rheumatic Disease Core Center (Core 2)
P30 AR 04736308/25/11-06/30/16$45,687

Geiger, H

Molecular Mechanisms and Therapies for Radiation-Induced Myelodysplastic Syndrome
04/01/12-03/31/17$181,818

Guo, F

Novel Signaling Function of Cdc42 GTPase in vivo
R01 GM 10866105/01/14-02/28/18$175,000

Hennigan, R

Regulation of Intracellular Trafficking in NF2
W81XWH131013606/01/13-05/31/16$133,290

Komurov, K

Modeling and Targeting the Hexosamine Pathway in Drug Resistance
08/01/13-07/31/16$120,000

Lu, Q

A Novel Model of Medulloblastoma to Define Cancer Pathways and Molecular Targets
R01 NS 07809210/01/13-03/31/17$349,062
Chromatin Remodeling Control of CNS Myelination and Remyelination
R01 NS 07524310/01/13-03/31/17$399,554
Chromatin Remodeling in Oligodendrocyte Myelination and Remyelination
RG4568A5T10/01/13-03/31/14$31,122
microRNA Control of Myelination and Remyelination in the Central Nervous System
RG4727A6T10/01/13-06/30/15$148,046
Molecular Mechanisms of Oligodendrocyte Differentiation and Myelination
R01 NS 07242710/01/13-08/31/15$138,615
Identification of Novel Small Molecules for CNS Myelin Repair
R21 NS 07721511/01/13-06/30/15$67,644

Malik, P

Ameliorating Sickle Nephropathy and Pulmonary Hypertension
R34 HL 10875208/18/11-06/30/14$142,800
Cincinnati Cell Characterization Core
U01 HL 09999709/01/10-04/30/15$50,862
Cincinnati Cell Characterization Core (per case reimbursement)
U01 HL 09999705/01/11-04/30/14$109,291
Cincinnati Center of Excellence in Hemoglobinopathies Research
U01 HL 11770908/15/13-05/31/18$1,169,344
Quinn, CTranslational Research Skills Development Core$258,435
Kalfa, TResearch Project 1$123,169
Malik, PResearch Project 2$548,319
Quinn, CResearch Project 3$222,743
Kalfa, TSummer Students$40,542
Gene Therapy for Sickle Cell Anemia
09/01/13-08/31/16$150,000
PLGF-H1F1a-mIRNA Axis in Sickle Pulmonary Hypertension
R01 HL 11137201/01/12-12/31/16$143,001

Mulloy, J

Genotype and Phenotype of Chemoresistant AML
R21 CA 16836903/01/13-02/28/15$105,488
Rac Signaling in MLL Leukemia
07/01/10-06/30/15$104,762
LSC Mobilization and Differentiation Therapy
09/01/13-12/31/15$250,000
Conferring In Vivo Metabolic Resistance to a Highly Selective Anti-AML Agent
R21 CA18537005/01/14-02/28/16$29,928

Nassar, N

Novel Rationally Designed Ras Inhibitors for B-ALL Multi-Target Therapy
10/01/13-09/30/16$180,018

Pan, D

Gaucher Disease: Treatment of Neurodegenerative Disease
R01 NS 08613409/01/13-05/31/18$270,887

Pang, Q

Role of FA Proteins in Hematopoiesis
R01 HL 07671204/01/10-03/31/15$242,550
Targeted Improvement in Stem Cell Therapy for Leukemia and Bone Marrow Failure Syndromes
R01 CA 15753702/01/11-12/31/15$186,750

Patel, A

Identification and Study of Novel Genes Critical to Survival of MPNST Cells
06/01/13-05/31/15$46,092

Ratner, N

Identification of Molecular and Cellular Contributors to Neurofibroma Formation and Growth
W81XWH121013307/01/12-06/30/15$225,000
Identification of Neurofibroma Growth and Drug Resistance Pathways
02/01/14-01/31/16$65,902
Mitogenic Activities in Neurofibromatosis
R01 NS 02884009/15/11-07/31/16$223,156
Neurofibroma Preclinical Therapeutics
07/15/13-07/14/16$287,661
Ras Proteins in Nerve Tumorigenesis
R01 NS 08358004/01/14-03/31/19$218,750
Regulation of GCPII for the Diagnosis and Treatment of Neurofibromas
05/01/14-04/30/15$33,085

Sampson, L

mTOR Signaling in Murine Intestinal Stem Cell and Progenitor Homeostasis
F32 DK 09787912/01/12-11/30/14$55,094

Springer, M

Training Programs in Cancer Therapeutics
T32 CA 1178608/01/13-07/31/15$39,265

Starczynowski, D

Defining the Role and Therapeutic Potential of TNF Receptor-Associated Factor 6 in Myelodysplastic Syndromes
06/01/13-05/31/16$68,182
Deregulation of TIFAB in Myelodysplastic Syndrome
07/01/11-06/30/14$50,000
Identification and Characterization of Genes in del(5q) Myelodysplastic Syndrome
R01 HL 11110312/15/11-11/30/16$245,000

Tandon, P

Characterizing the Role of Specific Ras Proteins in Neurofibroma and MPNST Formation
F32 NS 08324909/01/13-08/31/15$49,214

Varney, M

Environmental Carcinogenesis and Mutagensis
T32 ES00725005/01/12-04/30/15$46,092

Wu, L

Functional Study of Transcriptional Regulator Sip1 in CNS Myelination and Remyelination
10/01/13-09/30/16$51,642

Wu, J

STAT3 in Neurofibroma Tumorigenesis and Therapy
W81XWH111025907/01/11-06/30/14$137,415

Zheng, Y

Cincinnati Center for Excellence in Molecular Hematology
P30 DK 09097109/01/11-06/30/15$456,330
A Non-Myeloablative Conditioning Regimen for Hematopoietic Stem Cell Transplant
R34 HL11757602/17/14-02/16/15$86,732
Therapeutic Targeting of LARG-RhoA-ROCK Signaling Axis in Childhood Leukemia
07/01/13-06/30/15$125,000

Zheng, Y/ Geiger, H

Lineage Determination and Tissue Homeostasis in the Aged Hematopoietic System
R01 AG 04011808/01/11-07/31/16$212,625

Zheng, Y / Mulloy J

Targeting Cdc42 in Leukemia Stem Cells
R01 CA 15054703/10/10-01/31/15$195,237
Current Year Direct$8,832,677
Industry Contracts

Flick, M

$115,747

Grassman, E

$34,010

Mulloy, J

$7,261

Starczynowski, D

$33,433
Current Year Direct Receipts$190,451
Total$9,023,128